ADSTILADRIN® (nadofaragene firadenovec-vncg) logo
ADSTILADRIN® (nadofaragene firadenovec-vncg) logo
oggle navigation menu.

ADSTILADRIN is now FULLY AVAILABLE.

Introducing ADSTILADRIN

The FIRST and ONLY FDA-approved gene therapy delivered directly in the bladder for non–muscle-invasive bladder cancer

For when Bacillus Calmette-Guérin (BCG) treatment does not work.

“

As of August this year, I was told by my urologist that I was cancer free.

”
Watch Mike’s Story
A still profile image of Mike from his ADSTILADRIN testimonial video
Click to play video

Watch Mike’s Story

Mike, diagnosed with NMIBC and treated with ADSTILADRIN (ad-still-uh-drin)

Mike, diagnosed with NMIBC and treated with ADSTILADRIN (ad-still-uh-drin)

For when Bacillus Calmette-Guérin (BCG) treatment does not work.

  • Effective Icon

    Effective

  • Well Tolerated Icon

    Well Tolerated

  • Convenient Dosing Icon

    Convenient Dosing

Effective Icon

Effective

  • More than half of the people who took ADSTILADRIN in a clinical trial had a complete response (no signs of bladder cancer) after the first dose at 3 months1
    • Most people (74%) treated with ADSTILADRIN did not need to have their bladder removed (a procedure called cystectomy) at 1 year2
  • More than 1 in 3 (36%) people who had a complete response at 3 months were still bladder cancer free at 2 years3* 
     
    *This was part of a separate analysis that was done at a later time. Talk to your doctor about the limitations of these 2-year data.
Explore results
Well Tolerated Icon

Well Tolerated

  • Most side effects were mild and manageable and went away after 2 days4
    • 11% of people taking ADSTILADRIN had serious side effects1
  • 3 people had to stop ADSTILADRIN due to side effects1
Explore results
Convenient Dosing Icon

Convenient Dosing

  • Delivered once every 3 months into the bladder through a urinary catheter1
  • Given and managed by your urologist in their office
Explore results

FIND ON THIS PAGE

About non–muscle-invasive bladder cancer (NMIBC)

Understanding this specific type of cancer

Image indicating 3 out of 4 people with bladder cancer have NMIBC
About 3 out of 4 people with bladder cancer have NMIBC.5

The bladder is a part of our body where urine is stored.

NMIBC is bladder cancer that has not spread past the lining of the bladder into the muscle. It is the most common type of bladder cancer.6,7

KNOW YOUR OPTIONS

For early-stage bladder cancer, BCG is a common first therapy.6 But sometimes, BCG therapy can stop working. When you find that you need additional treatment for bladder cancer, you may be concerned about what comes next.

If BCG therapy stops working, there are only a few approved treatment options available to try before you may need to have your bladder removed.8 But there are reasons to feel hopeful—and treatments that may help you keep your bladder.

Patient Guide Icon

Learn how ADSTILADRIN, a first-of-its-kind gene therapy for NMIBC, can help.

Download Link

What is ADSTILADRIN?

Learn about ADSTILADRIN and how it works

What ADSTILADRIN is1

  • ADSTILADRIN is a gene therapy.
  • ADSTILADRIN delivers the gene that encodes for the interferon alfa-2b protein to your bladder so it can fight the cancer.
  • ADSTILADRIN is a targeted treatment. It works with your body’s immune cells.
  • ADSTILADRIN is a treatment that allows you to stay in the care of your urologist.

What ADSTILADRIN is not1

  • ADSTILADRIN is NOT chemotherapy.
  • ADSTILADRIN does not change your genes like some other gene therapies.
  • ADSTILADRIN ONLY fights the cancer in your bladder. It DOES NOT impact your overall immune system. This may help reduce side effects.
  • ADSTILADRIN does not require you to change providers for treatment.

Your healthcare team will talk to you about your options. Work closely with them to create a treatment plan that is made just for you.

ADSTILADRIN was shown to be well tolerated and effective

ADSTILADRIN was studied in 98 people with high-risk NMIBC whose cancer did not respond to BCG therapy.1

WELL TOLERATED

  • Most side effects were mild and manageable and went away after 2 days4
    • 11% of people on ADSTILADRIN had serious side effects1
  • 3 people had to stop ADSTILADRIN due to side effects1
  • There were no deaths due to treatment-related side effects with ADSTILADRIN1
    • 34% of people paused treatment due to side effects but then continued treatment1

EFFECTIVE

At 3 months:

51%

  • More than half of the people who took ADSTILADRIN had a complete response (no signs of bladder cancer) after the first dose1
    • Of this group, almost half (46%) stayed bladder cancer free for a year or longer1

At 1 year:

74%

  • Most people treated with ADSTILADRIN did not need to have their bladder removed2

Almost everyone (95%) given ADSTILADRIN did not have their cancer spread outside of the bladder2

At 2 years:

Image indicating more than 1 in 3 people (36%) who had a complete response at 3 months were still bladder cancer free
  • More than 1 in 3 people (36%) who had a complete response at 3 months were still bladder cancer free3*

*This was part of a separate analysis that was done at a later time. Talk to your doctor about the limitations of these 2-year data.

Treatment with ADSTILADRIN

What to expect when taking ADSTILADRIN

Bladder icon with ADSTILADRIN dosing icon
ADSTILADRIN is delivered directly into the bladder by your urologist every 3 months

ADSTILADRIN is delivered using a catheter that goes directly into your bladder. This is like the process for BCG treatment.1

The post-treatment directions are like those for after BCG treatment as well.

Stethoscope icon

ADSTILADRIN is given by your urologist in their office

Your urologist will also manage your care after treatment, so your healthcare team will conveniently remain the same.

Meet Mike, who was treated with ADSTILADRIN, and hear his story

Download “Getting Started With ADSTILADRIN” for more details about treatment

What to expect after completing your first treatment with ADSTILADRIN

Some side effects may occur after taking ADSTILADRIN. The most common side effects of ADSTILADRIN include1:

Bladder icon with warnings
  • Urinary discharge
  • Urgency to urinate
  • Fatigue
  • Blood in your urine
  • Bladder spasm

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects if they continue for more than 2 days after treatment. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088. You may also report side effects to Ferring Pharmaceuticals at 1-888-337-74641-888-337-7464, option 1.

Other important things to consider

Your healthcare team may suggest keeping movement to a minimum.

  • Ask your team if they suggest any movement restrictions after you have received treatment

After your first dose, your doctor may monitor how well ADSTILADRIN is working.

  • They will do this with a procedure that uses a thin, tubelike instrument with a light that allows the doctor to view the inside of your bladder
ADSTILADRIN Dosing Icon

ADSTILADRIN is given every 3 months—talk with your healthcare provider about scheduling your next appointment.1

ADSTILADRIN support and resources

Ferring is here to help support you during your treatment

Ferring Access Support is a program that offers patient assistance, coverage support, and other valuable resources

HOW IT WORKS

  1. Your healthcare provider will help you enroll in Ferring Access Support.
  2. After that, a Ferring Access Support case manager will contact you to help you learn more about what to expect during the process.
  3. They may also reach out if there is any missing information in your profile or to remind you of an upcoming appointment.
ADSTILADRIN patient portrayal image

SERVICES OFFERED

Benefits
investigation support

Financial assistance for patients

Dedicated
reimbursement support

ADSTILADRIN patient portrayal image
Telephone icon

Ferring Access Support

1-844-623-66691-844-623-6669
Monday to Friday, 9 am to 6 pm eastern time

Your case manager will work with your health insurer to determine whether ADSTILADRIN is covered by your plan. They can also share information about other programs, such as the ADSTILADRIN Copay Program or Ferring Access Support Patient Assistance Program, to help you get access to ADSTILADRIN. Terms and conditions apply.

Resources to learn more

Download the following materials for more information about ADSTILADRIN.

Download Link
Downloadable guide for patients getting started with ADSTILADRIN

Getting Started With ADSTILADRIN: For Patients

Download Link
Downloadable ADSTILADRIN prescribing information

ADSTILADRIN Prescribing Information

References: 1. ADSTILADRIN. Package insert. Ferring Pharmaceuticals, Inc; 2023. 2. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107-117. doi:10.1016/S1470-2045(20)30540-4 3. Schuckman AK, Lotan Y, Boorjian SA, Cilwa KE, Dinney CPN. Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): longer-term follow-up from the phase III trial. J Urol. 2021;206(suppl 3):e296. doi:10.1097/JU.0000000000002001.01 4. Data on file. ADSTILADRIN CSR, Ferring Pharmaceuticals, Inc. Parsippany, NJ. 5. European Association of Urology. Guidelines for non-muscle-invasive bladder cancer (TaT1 and CIS). Updated March 2023. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer 6. American Cancer Society. Intravesical therapy for bladder cancer. Accessed July 6, 2023. https://www.cancer.org/cancer/types/bladder-cancer/treating/intravesical-therapy.html 7. National Health Service. Overview: bladder cancer. Accessed April 20, 2023. https://www.nhs.uk/conditions/bladder-cancer 8. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533-538. doi:10.1097/JU.0000000000003846

Important Safety Information

INDICATION

ADSTILADRIN is a treatment for adults who have all the following:

  • High-risk non–muscle-invasive bladder cancer
  • Cancer that is no longer responding to Bacillus Calmette-Guérin (BCG) therapy
  • Cancer that started in the bladder and has not spread (this is called carcinoma in situ or CIS)
  • Cancer with or without slender, finger-like tumor growths (papillary tumors) growing into the bladder space, away from the bladder wall

IMPORTANT SAFETY INFORMATION

Who should not receive ADSTILADRIN?
Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components.

What is the most important information I should know about ADSTILADRIN?
Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive or come into contact with ADSTILADRIN.

What should I tell my healthcare provider?
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ADSTILADRIN?
The most common side effects of ADSTILADRIN include:
Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine.

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

What other information should I know about using ADSTILADRIN?
For 2 days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing.

For more important information, call 1-888-337-74641-888-337-7464.

Please see full Prescribing Information.

AVAILABILITY

ADSTILADRIN is now fully available across the United States.

Treatment starts with a conversation. Ask your doctor about ADSTILADRIN today.

For more information, contact us at
‍1-888-FERRING
(1-888-337-7464)(‍1-888-337-7464) and select option 1.